System maintenance is scheduled for 11 Sep, 08:00 PM - 12 Sep, 00:00 AM CST [12 Sep 03:00 AM to 07:00 AM CET] and will affect some web and offline transactions, including quotes, price checks, and order status inquiries. We apologize for any inconvenience.
A potent ATP-competitive RIP3 (RIPK3) kinase inhibitor that suppresses necrosis induction in both human and murine cell cultures.
GSK′843 is a potent ATP-competitive RIP3 (RIPK3) kinase inhibitor (IC50 = 6.5 nM) with much reduced or little affinity toward 262 other kinases (IC50 >1 μM against 10 μM ATP in competitive binding assay), including RIP5. GSK′843 effectively suppresses TNF/Z-VAD-FMK/IAP agonist treatment-induced necrosis induction in both human and murine cell cultures (EC50 ranges from <0.12 to 3 μM), while inducing apoptosis in the absence of caspase inhibitor as a result of caspase 8 activation via RHIM-driven recruitment to assemble a Casp8-FADD-cFLIP complex independent of pronecrotic kinase activities and MLKL.